Clinical Trials | April 05, 2024
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Subscribe To Our Newsletter & Stay Updated
